Peregrine Capital Management LLC Has $7.32 Million Holdings in TransMedics Group, Inc. $TMDX

Peregrine Capital Management LLC cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 12.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,157 shares of the company’s stock after selling 8,249 shares during the quarter. Peregrine Capital Management LLC’s holdings in TransMedics Group were worth $7,318,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. HB Wealth Management LLC boosted its position in TransMedics Group by 1.8% during the 4th quarter. HB Wealth Management LLC now owns 14,736 shares of the company’s stock worth $1,793,000 after acquiring an additional 258 shares during the period. M&T Bank Corp boosted its position in TransMedics Group by 749.2% during the 4th quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock worth $2,259,000 after acquiring an additional 16,385 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in TransMedics Group by 41.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 92,446 shares of the company’s stock worth $11,246,000 after acquiring an additional 27,101 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in TransMedics Group by 63.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,265 shares of the company’s stock worth $1,979,000 after acquiring an additional 6,325 shares during the period. Finally, First Horizon Corp boosted its position in TransMedics Group by 83.8% during the 4th quarter. First Horizon Corp now owns 702 shares of the company’s stock worth $85,000 after acquiring an additional 320 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $113.21 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. TransMedics Group, Inc. has a fifty-two week low of $88.50 and a fifty-two week high of $156.00. The stock’s 50-day moving average is $120.20 and its two-hundred day moving average is $126.21. The firm has a market cap of $3.91 billion, a P/E ratio of 23.10 and a beta of 2.09.

Insider Buying and Selling

In other TransMedics Group news, CFO Gerardo Hernandez sold 7,236 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the transaction, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at $2,162,367.69. This represents a 33.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David Weill sold 3,571 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total value of $524,294.22. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,781,513.88. The trade was a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 16,205 shares of company stock worth $2,353,002. Insiders own 6.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TMDX shares. Piper Sandler raised their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of TransMedics Group in a research report on Monday, March 16th. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Stifel Nicolaus lifted their price objective on TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research report on Monday, March 9th. Finally, Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $152.33.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.